Technology evaluation: MG-98, MethylGene

Current Opinion in Molecular Therapeutics

Volumn 3, Issue 6, 2001, Pages 599-604

  Zhang, Z ^a  

^a EPIX Medical Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; DNA METHYLTRANSFERASE; MESSENGER RNA; METHYLTRANSFERASE INHIBITOR; MG 88; MG 98;

ADULT; ADVANCED CANCER; AGED; ANOREXIA; ARTICLE; BIOTECHNOLOGY; CANCER INHIBITION; CHILL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG CONTRAINDICATION; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; ENZYME INHIBITION; EVALUATION; FATIGUE; FEMALE; FEVER; GENE SEQUENCE; HEAD AND NECK CANCER; HUMAN; HUMAN CELL; KIDNEY CARCINOMA; MALE; METASTASIS; PATENT; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; RECURRENT CANCER; SOLID TUMOR; SQUAMOUS CELL CARCINOMA;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS; HUMANS; NEOPLASMS; OLIGONUCLEOTIDES, ANTISENSE;

EID: 0035676719     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. MethylGene initiates phase I clinical trials of MG98 for solid tumor cancers novel inhibitor of DNA methyltransferase
2. The commercial-scale production of oligonucleotides
3. Novel mechanisms for antisense-mediated regulation of gene expression
4. Hybridon receives United States and European patents on improved gene-based antisense drugs
5. Antisense inhibitors to nucleotide excision repair protein identified
6. Avecia to acquire Hybridon's DNA manufacturing business for US $15 million
7. MGI PHARMA and MethylGene Sign license, research and development agreement for two novel anti-cancer programs - Antitumor activity seen in phase I human clinical trials of MG98
8. Gene therapy: Recent progress in the clinical oncology arena
9. Hybridon consolidates operations in Cambridge facility
10. Hybridon sells DNA manufacturing business
11. A phase I and pharmacokinetic (PK) study of human DNA methyltransferase (METASE) antisense oligodeoxynucleotide MG-98 given as a 21-day continuous infusion every 4 weeks
12. MethylGene Inc raises $18.6 million in private financing: Strong institutional investor backing for drug discovery and development programs
13. MGI Pharma reports financial results for third quarter of 2000
14. Hybridon announces issuance of a dominant second generation antisense patent
15. GEM(R)231 safely used with taxanes in cancer patients; clinical data presented at leading cancer meeting
16. Phase I and pharmacodynamic study of human DNA methyltransferase (MeTase) antisense oligodeoxynucleotide (ODN), MG98, adminstered as 21 day infusion q4 weekly
17. MGI Pharma and MethylGene commence phase 2 trial of MG98 to treat head and neck cancer
18. NCI-EORTC-AACR 11th Symposium on New Drugs in Cancer Therapy
19. Antisense approaches for the treatment of cancer
20. A phase I and pharmacokinetic (PK) study of MG98, a human DNA methyltransferase (Metase) antisense olignucleotide, given as an 2-hour twice weekly (BIW) infusion 3 out of every 4 weeks
21. The delivery of antisense therapeutics
22. MGI Pharma reports financial results for 2000
23. Making sense of antisense
24. MGI PHARMA reports 2001 first quarter results
25. MGI PHARMA announces issuance of key patent for inhibition of DNA methyltransferase
26. MethylGene Inc receives key patent for inhibition of DNA methyltransferase: Patent provides further IP protection for company's innovative area of research
27. MGI PHARMA and MethylGene initiate phase II Trial of MG98 in renal cell (kidney) carcinoma
28. MGI PHARMA reports 2001 third quarter results - Both phase III programs continue to progress
29. MGI PHARMA and MethylGene announce data presented at 2001 AACR-sponsored epigenetics of cancer conference
30. Antisense therapy in oncology: New hope for an old idea?
31. The delivery of antisense therapeutics
32. DNA methyltransferase genomic sequences and antisense oligonucleotides
33. Optimized antisense oligonucleotides complementary to DNA methyltransferase sequences
34. DNA methyltransferase genomic sequences and antisense oligonucleotides
35. WAF/Cip1 by distinct mechanisms
36. Characterization of the human DNA methyltransferase splice variant Dnmt1b
37. Targeting gene regulators for cancer therapy